China Pharma Holdings, Inc. (CPHI)
USD 1.53
(-1.93%)
USD 1.53
(-1.93%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.47 Million USD | -28.64% |
| 2022 | 3.14 Million USD | -9.12% |
| 2021 | 3.46 Million USD | -21.54% |
| 2020 | 4.41 Million USD | -9.36% |
| 2019 | 4.87 Million USD | 139.22% |
| 2018 | -12.42 Million USD | 41.26% |
| 2017 | -21.14 Million USD | -85.94% |
| 2016 | -11.37 Million USD | 27.85% |
| 2015 | -15.76 Million USD | 61.95% |
| 2014 | -41.42 Million USD | -89.8% |
| 2013 | -21.82 Million USD | -167.1% |
| 2012 | -8.17 Million USD | -217.36% |
| 2011 | 6.96 Million USD | 14.37% |
| 2010 | 6.08 Million USD | 100.52% |
| 2009 | 3.03 Million USD | -45.4% |
| 2008 | 5.56 Million USD | 67.68% |
| 2007 | 3.31 Million USD | 124.97% |
| 2006 | 1.47 Million USD | 496.67% |
| 2005 | 247.03 Thousand USD | 165.73% |
| 2004 | 92.96 Thousand USD | -65.01% |
| 2003 | 265.72 Thousand USD | -64.68% |
| 2002 | 752.32 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 628.09 Thousand USD | -39.78% |
| 2024 Q2 | 271.21 Thousand USD | -56.82% |
| 2023 Q2 | 305.6 Thousand USD | -47.8% |
| 2023 FY | 2.24 Million USD | -28.64% |
| 2023 Q1 | 585.43 Thousand USD | -52.09% |
| 2023 Q3 | 498.56 Thousand USD | 63.14% |
| 2023 Q4 | 1.04 Million USD | 109.22% |
| 2022 Q2 | 554.57 Thousand USD | -25.84% |
| 2022 Q3 | 624.73 Thousand USD | 12.65% |
| 2022 FY | 3.14 Million USD | -9.12% |
| 2022 Q1 | 747.77 Thousand USD | 178.66% |
| 2022 Q4 | 1.22 Million USD | 95.58% |
| 2021 FY | 3.46 Million USD | -21.54% |
| 2021 Q1 | -969.19 Thousand USD | 41.72% |
| 2021 Q2 | -823.94 Thousand USD | 14.99% |
| 2021 Q3 | -466 Thousand USD | 43.44% |
| 2021 Q4 | -950.62 Thousand USD | -103.99% |
| 2020 Q1 | -793.71 Thousand USD | 95.81% |
| 2020 FY | 4.41 Million USD | -9.36% |
| 2020 Q3 | -999.69 Thousand USD | 6.99% |
| 2020 Q2 | -1.07 Million USD | -35.41% |
| 2020 Q4 | -1.66 Million USD | -66.35% |
| 2019 Q1 | -990.73 Thousand USD | 86.5% |
| 2019 FY | 4.87 Million USD | 139.22% |
| 2019 Q3 | -1.01 Million USD | -11.07% |
| 2019 Q2 | -916.51 Thousand USD | 7.49% |
| 2019 Q4 | -18.96 Million USD | -1763.02% |
| 2018 FY | -12.42 Million USD | 41.26% |
| 2018 Q4 | -7.34 Million USD | -200.33% |
| 2018 Q3 | -2.44 Million USD | -69.26% |
| 2018 Q2 | -1.44 Million USD | -20.89% |
| 2018 Q1 | -1.19 Million USD | 91.69% |
| 2017 Q2 | -2.77 Million USD | -82.82% |
| 2017 Q3 | -2.47 Million USD | 10.9% |
| 2017 Q4 | -14.37 Million USD | -480.22% |
| 2017 FY | -21.14 Million USD | -85.94% |
| 2017 Q1 | -1.52 Million USD | 68.39% |
| 2016 Q4 | -4.81 Million USD | -153.47% |
| 2016 FY | -11.37 Million USD | 27.85% |
| 2016 Q1 | -1.96 Million USD | 68.15% |
| 2016 Q2 | -2.7 Million USD | -37.79% |
| 2016 Q3 | -1.89 Million USD | 29.81% |
| 2015 Q4 | -6.16 Million USD | -314.56% |
| 2015 Q2 | -3.74 Million USD | 57.05% |
| 2015 Q1 | -8.72 Million USD | 51.47% |
| 2015 FY | -15.76 Million USD | 61.95% |
| 2015 Q3 | 2.87 Million USD | 176.62% |
| 2014 Q1 | -4.99 Million USD | 41.61% |
| 2014 Q2 | -10.94 Million USD | -119.03% |
| 2014 Q3 | -7.5 Million USD | 31.46% |
| 2014 Q4 | -17.98 Million USD | -139.74% |
| 2014 FY | -41.42 Million USD | -89.8% |
| 2013 Q1 | -1.43 Million USD | 47.5% |
| 2013 Q2 | -6.91 Million USD | -382.76% |
| 2013 Q3 | -4.92 Million USD | 28.74% |
| 2013 Q4 | -8.55 Million USD | -73.78% |
| 2013 FY | -21.82 Million USD | -167.1% |
| 2012 Q4 | -2.72 Million USD | -67.71% |
| 2012 FY | -8.17 Million USD | -217.36% |
| 2012 Q3 | -1.62 Million USD | 15.66% |
| 2012 Q2 | -1.92 Million USD | -201.97% |
| 2012 Q1 | 1.89 Million USD | 1194.82% |
| 2011 FY | 6.96 Million USD | 14.37% |
| 2011 Q4 | 146 Thousand USD | -95.96% |
| 2011 Q3 | 3.61 Million USD | 102.56% |
| 2011 Q2 | 1.78 Million USD | 16.68% |
| 2011 Q1 | 1.53 Million USD | -23.96% |
| 2010 Q4 | 2.01 Million USD | 52.24% |
| 2010 Q3 | 1.32 Million USD | -14.88% |
| 2010 FY | 6.08 Million USD | 100.52% |
| 2010 Q2 | 1.55 Million USD | 18.92% |
| 2010 Q1 | 1.3 Million USD | -16.26% |
| 2009 Q2 | 1.11 Million USD | -40.11% |
| 2009 FY | 3.03 Million USD | -45.4% |
| 2009 Q4 | 1.56 Million USD | 203.5% |
| 2009 Q3 | -1.5 Million USD | -234.92% |
| 2009 Q1 | 1.86 Million USD | 30.72% |
| 2008 Q2 | 1.55 Million USD | 35.0% |
| 2008 Q4 | 1.42 Million USD | 135.0% |
| 2008 FY | 5.56 Million USD | 67.68% |
| 2008 Q3 | -4.07 Million USD | -361.86% |
| 2008 Q1 | 1.15 Million USD | 439.99% |
| 2007 FY | 3.31 Million USD | 124.97% |
| 2007 Q4 | -339.3 Thousand USD | -144.83% |
| 2007 Q1 | 2.36 Million USD | 184.66% |
| 2007 Q2 | 534.07 Thousand USD | -77.41% |
| 2007 Q3 | 756.78 Thousand USD | 41.7% |
| 2006 Q2 | 518.47 Thousand USD | 47.2% |
| 2006 Q1 | 352.23 Thousand USD | 0.0% |
| 2006 Q3 | 421.11 Thousand USD | -18.78% |
| 2006 Q4 | 830.58 Thousand USD | 97.23% |
| 2006 FY | 1.47 Million USD | 496.67% |
| 2005 Q2 | 1.77 Million USD | 4260.15% |
| 2005 FY | 247.03 Thousand USD | 165.73% |
| 2005 Q1 | 40.67 Thousand USD | 134.36% |
| 2005 Q3 | 289.16 Thousand USD | -83.7% |
| 2004 Q3 | 10.72 Thousand USD | -61.61% |
| 2004 Q4 | 17.35 Thousand USD | 61.85% |
| 2004 FY | 92.96 Thousand USD | -65.01% |
| 2004 Q2 | 27.93 Thousand USD | 1005.9% |
| 2004 Q1 | 2526.00 USD | 348.67% |
| 2003 Q4 | 563.00 USD | -99.39% |
| 2003 Q2 | 153.99 Thousand USD | 487.67% |
| 2003 Q1 | 26.2 Thousand USD | -40.46% |
| 2003 Q3 | 91.64 Thousand USD | -40.49% |
| 2003 FY | 265.72 Thousand USD | -64.68% |
| 2002 FY | 752.32 Thousand USD | 0.0% |
| 2002 Q4 | 44.01 Thousand USD | 6.04% |
| 2002 Q3 | 41.5 Thousand USD | -65.92% |
| 2002 Q2 | 121.77 Thousand USD | -65.71% |
| 2002 Q1 | 355.17 Thousand USD | 216.24% |
| 2001 Q4 | 112.31 Thousand USD | -31.12% |
| 2001 Q3 | 163.06 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| cbdMD, Inc. | 24.24 Million USD | 89.81% |
| cbdMD, Inc. | 24.24 Million USD | 89.81% |
| Zomedica Corp. | 48.91 Million USD | 94.948% |